A permission system for carbapenem use reduced incidence of drug-resistant bacteria and cost of antimicrobials at a general hospital in japan

Nagoya Journal of Medical Science

Volumn 74, Issue 1-2, 2012, Pages 93-104

  Ikeda, Yoshiaki ^a,b   Mamiya, Takayoshi ^b,c   Nishiyama, Hideki ^a   Narusawa, Shiho ^b   Koseki, Takenao ^b   Mouri, Akihiro ^b   Nabeshima, Toshitaka ^b,c  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c Japanese Drug Organization of Appropriate Use and Research   (Japan)

Author keywords

Antimicrobial; ATC DDD system; Carbapenem; Drug resistant bacteria; Permission system

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG UTILIZATION; ECONOMICS; ESCHERICHIA COLI INFECTION; EVALUATION; FEASIBILITY STUDY; GENERAL HOSPITAL; HEALTH CARE QUALITY; HOSPITAL COST; HOSPITAL INFORMATION SYSTEM; HOSPITAL PHARMACY; HUMAN; INAPPROPRIATE PRESCRIBING; INFECTION CONTROL; JAPAN; KLEBSIELLA INFECTION; METHODOLOGY; MICROBIOLOGY; ORGANIZATION AND MANAGEMENT; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; TIME;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI INFECTIONS; FEASIBILITY STUDIES; HOSPITAL COSTS; HOSPITALS, GENERAL; HUMANS; INAPPROPRIATE PRESCRIBING; INFECTION CONTROL; JAPAN; KLEBSIELLA INFECTIONS; MEDICAL ORDER ENTRY SYSTEMS; PHARMACY SERVICE, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; PROGRAM EVALUATION; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84860649677     PISSN: 00277622     EISSN: 21863326     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. Comparative review of the carbapenems. Drugs, 2007; 67: 1027-1052.
2. Baughman RP. The use of carbapenems in the treatment of serious infections. J Intensive Care Med, 2009; 24: 230-241.
3. Craig WA, Uman SJ, Shaw WR, Ramgopal V, Eagan LL, Leopold ET. Hospital use of antimicrobial drugs. Survey at 19 hospitals and results of antimicrobial control program. Ann Intern Med, 1978; 89: 793-795.
4. Woodward RS, MedoffG, Smith MD, Gray JL 3rd. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med, 1987; 83: 817-823.
5. Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, O'Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med, 1991; 90: 439-444.
6. Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. Am J Health Syst Pharm, 1995; 52: 1433-1435.
7. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis, 1997; 25: 230-239.
8. Cannon JP, Silverman RM. A pharmacist-driven antimicrobial approval program at a Veterans Affairs hospital. Am J Health Syst Pharm, 2003; 60: 1358-1362.
9. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis, 1999; 29: 245-252.
10. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol, 2004; 58: 419-428.
11. Monnet DL. Toward multinational antimicrobial resistance surveillance systems in Europe. Int J Antimicrob Agents, 2000; 15: 91-101. Review.
12. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother, 2004; 53: 290-296.
13. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis, 2007; 44: 159-177.
14. Centers for Disease Control and Prevention. 2006. Management of multidrug-resistant organisms in healthcare settings. http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf
15. Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis, 1998; 17: 20-24.
16. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/
17. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational Supplement. CLSI document M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Muro T, Hideshima R, Nakamura K, Kamimura H. Effort to promote proper use of anti methicillin-resistant Staphylococcus aureus agents and carbapenems. Jpn J Chemother, 2006; 54: 511-519. (in Japanese)
19. Hara T, Kasai M, Yoda T, Arai S, Ishii K, Hayashi H. Appropriate use of antimicrobial agents in maternity center and children's hospital: Effects of antimicrobial use notification policy and intervention by infection control team. Jpn J Environ Infect, 2007; 22: 253-259. (in Japanese)
20. Tanaka D, Fukasawa S, Kiko Y, Kinoshita K, Sakaguchi M, Fujie T. Effects of use notification policy for various classes of antimicrobial agents on consumption of antimicrobial agents and antimicrobial resistance. Jpn J Environ Infect, 2008; 23: 361-365. (in Japanese)
21. Kimura T, Kai T, Nishiumi K, Takahashi H, Sasaki H. Effect of ICT intervention on the trend of antimicrobial use and drug resistant bacteria. Jpn J Environ Infect, 2009; 24: 405-410. (in Japanese)
22. Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, Tanimoto M, Masaoka T. and Japan Febrile Neutropenia Study Group. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis, 2004; 39: S15-24.
23. Ploy MC, Grélaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet, 1998; 351: 1212.
24. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis, 2005; 41: 848-854.
25. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Fishman NO, Bilker WB, Mao X, Lautenbach E. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis, 2005; 40: 1317-1324.
26. http://www.jshp.or.jp/senmon/senmon2.html (in Japanese)
27. Centers for Disease Control and Prevention (CDC). Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC), MMWR 44, No. RR-12, 1995. http://ftp.cdc.gov/pub/Publications/mmwr/rr/rr4412.pdf
28. Hirschman S, Meyers BR, Bradbury K, Mehl B, Gendelman S, Kimelblatt B. Use of antimicrobial agents in a university teaching hospital. Evolution of a comprehensive control program. Arch Intern Med, 1988; 148: 2001-2007. Review.
29. Gums JG, Yancey RW Jr, Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy, 1999; 19: 1369-1377.
30. Rifenburg RP, Paladino JA, Hanson SC, Tuttle JA, Schentag JJ. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health Syst Pharm, 1996; 53: 2054-2062.
31. Gould IM, Jappy B. Trends in hospital antimicrobial prescribing after 9 years of stewardship. J Antimicrob Chemother, 2000; 45: 913-917.